The analysis of cell-free DNA (ccfDNA) derived from serum or plasma is an established method for mutational screening in cancer diagnosis, prognosis and patient stratification. Liquid biopsy NGS applications offer highly sensitive, efficient and optimized workflows. The ccfDNA concentration in serum or plasma is normally very low, which makes sequencing library construction challenging. In this webinar, we will describe the technical challenges associated with ccfDNA sequencing and outline QIAGEN’s optimized ccfDNA workflow that combines high-efficiency NGS library construction with unbiased library amplification.